natgillin/translations-raw huggingface dataset:
Advagraf is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to maximum blood concentration (Cmax ) of approximately 2 hours (tmax).
Advagraf je formulacija takrolimusa s produljenim oslobađanjem što rezultira produljenim apsorpcijskim profilom nakon peroralne primjene uz srednje vrijeme do postizanja maksimalne koncentracije u krvi (Cmax) od otprilike 2 sata (tmax).
Advagraf is used to control your body’s immune response, enabling your body to accept the transplanted organ.
Advagraf se primjenjuje za obuzdavanje imunološkog odgovora tijela, čime mu se omogućuje da prihvati presađeni organ.
Advagraf reduces your body’s defence mechanism (immune system), which will not be as good at fighting infections.
Advagraf slabi obrambene mehanizme tijela (imunološki sustav), koji neće biti tako učinkovit u obrani od infekcija kao obično.
Advagraf therapy requires careful monitoring by adequately qualified and equipped personnel.
Liječenje Advagrafom mora biti pod strogim nadzorom odgovarajuće obučenih i opremljenih zdravstvenih djelatnika.
Advanced Accelerator Applications S.r.l, 47014 Meldola (FO), Italy
Advanced Accelerator Applications S.r.l, 47014 Meldola (FO), Italija
Advanced Accelerator Applications Technopole de l’Aube 14 rue Gustave Eiffel 10430 Rosières près Troyes France
Advanced Accelerator Applications Technopole de l’Aube 14 rue Gustave Eiffel 10430 Rosières près Troyes Francuska
Advanced Accelerator Applications, 01630, Saint Genis Pouilly, France
Advanced Accelerator Applications, 01630, Saint Genis Pouilly, Francuska
Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italy
Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italija
Advanced Accelerator Applications, 47014, Meldola, Italy
Advanced Accelerator Applications, 47014, Meldola, Italija
Advanced Accelerator Applications, 50100, Zaragoza, Spain
Advanced Accelerator Applications, 50100, Zaragoza, Španjolska
Advanced Accelerator Applications, 62660, Beuvry, France
Advanced Accelerator Applications, 62660, Beuvry, Francuska
Advanced Accelerator Applications, 86077, Pozzilli, Italy
Advanced Accelerator Applications, 47014, Meldola, Italija
Advanced Accelerator Applications, 86077, Pozzilli, Italy
Advanced Accelerator Applications, 86077, Pozzilli, Italija
Advanced Accelerator Applications, Technopole de l’Aube,10430 Rosières près Troyes, France
Advanced Accelerator Applications, Technopole de l’Aube,10430 Rosières près Troyes, Francuska
advanced cervical cancer if surgery or radiotherapy treatment is not possible.
uznapredovalog raka vrata maternice ako kirurški zahvat ili zračenje nije moguće provesti.
Advanced cirrhosis and post-liver transplant (ALLY-1)
Bolesnici s uznapredovalom cirozom i bolesnici kojima je presađena jetra (ALLY-1)
advanced gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro-oesophageal junction adenocarcinoma).
gastrični karcinom (rak želuca) u naprednom stadiju ili karcinom područja u kojem jednjak (ezofagus) ulazi u želudac (poznat pod nazivom adenokarcinom gastroezofagealnog spoja).
Advanced glaucoma which cannot be adequately controlled by medicinal products alone.
uznapredovali glaukom koji ne može biti kontroliran na odgovarajući način samo lijekovima.
advanced melanoma (a type of skin cancer) in adults
uznapredovalog melanoma (jedne vrste raka kože) u odraslih osoba
advanced melanoma, a type of skin cancer that has spread to other parts of the body or cannot be surgically removed.
uznapredovalim melanomom, vrstom raka kože koji se proširio na druge dijelove tijela ili se ne može kirurški ukloniti.
Advanced neuroendocrine tumours of pancreatic origin (pNET)
Uznapredovali neuroendokrini tumori s primarnim sijelom u gušterači (pNET)
advanced non-small cell lung cancer (a type of lung cancer) in adults advanced renal cell carcinoma (advanced kidney cancer) in adults.
uznapredovalog raka pluća nemalih stanica (jedne vrste raka pluća) u odraslih uznapredovalog karcinoma bubrežnih stanica (uznapredovalog raka bubrega) u odraslih
advanced non-small cell lung cancer in patients whose cancer cells are not mainly of the squamous type, where it is given with platinum-based chemotherapy; advanced non-small cell lung cancer in patients whose cancer cells have a certain change (‘activating mutations’) in the gene for a protein called EGFR, where it is given in combination with erlotinib; advanced or metastatic kidney cancer, in combination with interferon alfa-2a;
uznapredovalog raka nemalih stanica pluća u bolesnika čije stanice raka uglavnom nisu skvamozne, te se primjenjuje s kemoterapijom na bazi platine; uznapredovalog raka nemalih stanica pluća u bolesnika čije su stanice raka promijenjene („aktivirajuće mutacije”) u genu bjelančevine naziva EGFR, te se primjenjuje u kombinaciji s erlotinibom; uznapredovalim i/ili metastatskim rakom bubrežnih stanica, u kombinaciji s interferonom alfa-2a
advanced renal cell carcinoma (a type of kidney cancer) when anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used; differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland) when the cancer has progressed or spread locally or to other parts of the body and does not respond to treatment with radioactive iodine.
uznapredovali karcinom bubrežnih stanica (tip raka bubrega) u slučaju kada protutumorska terapija interferonom alfa ili interleukinom 2 nije bila uspješna ili se nije mogla primijeniti; diferencirani karcinom štitnjače (tip raka koji potječe iz folikularnih stanica štitnjače) u slučaju kada je karcinom uznapredovao ili se lokalno proširio u druge dijelove tijela i ne odgovara na liječenje radioaktivnim jodom.
ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 1000 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 1000 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 1000 IU powder and solvent for solution for injection.
ADVATE 1000 IU prašak i otapalo za otopinu za injekciju
ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa
ADVATE 1500 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 1500 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 1500 IU powder and solvent for solution for injection.
ADVATE 1500 IU prašak i otapalo za otopinu za injekciju
ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 2000 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 2000 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 2000 IU powder and solvent for solution for injection.
ADVATE 2000 IU prašak i otapalo za otopinu za injekciju
ADVATE 250 IU powder and solvent for solution for injection ADVATE 500 IU powder and solvent for solution for injection ADVATE 1000 IU powder and solvent for solution for injection ADVATE 1500 IU powder and solvent for solution for injection
ADVATE 250 IU prašak i otapalo za otopinu za injekciju ADVATE 500 IU prašak i otapalo za otopinu za injekciju ADVATE 1000 IU prašak i otapalo za otopinu za injekciju ADVATE 1500 IU prašak i otapalo za otopinu za injekciju
ADVATE 250 IU powder and solvent for solution for injection ADVATE 500 IU powder and solvent for solution for injection ADVATE 1000 IU powder and solvent for solution for injection ADVATE 1500 IU powder and solvent for solution for injection ADVATE 2000 IU powder and solvent for solution for injection ADVATE 3000 IU powder and solvent for solution for injection
ADVATE 250 IU prašak i otapalo za otopinu za injekciju ADVATE 500 IU prašak i otapalo za otopinu za injekciju ADVATE 1000 IU prašak i otapalo za otopinu za injekciju ADVATE 1500 IU prašak i otapalo za otopinu za injekciju ADVATE 2000 IU prašak i otapalo za otopinu za injekciju ADVATE 3000 IU prašak i otapalo za otopinu za injekciju
ADVATE 250 IU powder and solvent for solution for injection Octocog alfa
ADVATE 250 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 250 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 250 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 250 IU powder and solvent for solution for injection.
ADVATE 250 IU prašak i otapalo za otopinu za injekciju
ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 3000 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 3000 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 3000 IU powder and solvent for solution for injection.
ADVATE 3000 IU prašak i otapalo za otopinu za injekciju
ADVATE 500 IU powder and solvent for solution for injection Octocog alfa
ADVATE 500 IU prašak i otapalo za otopinu za injekciju oktokog alfa
ADVATE 500 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 500 IU prašak i otapalo za otopinu za injekciju oktokog alfa (rekombinantni ljudski koagulacijski faktor VIII)
ADVATE 500 IU powder and solvent for solution for injection.
ADVATE 500 IU prašak i otapalo za otopinu za injekciju
ADVATE has no influence on your ability to drive or to use machines.
ADVATE nema utjecaja na sposobnost upravljanja vozilima ili strojevima.
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 2 ml solvent are preassembled with the system for reconstitution).
ADVATE u sustavu BAXJECT III: Jedno pakiranje sastoji se od sustava BAXJECT III spremnog za uporabu, u hermetički zatvorenom blisteru (bočica s praškom i bočica s 2 ml otapala već su pričvršćene na sustav za rekonstituciju).
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 5 ml solvent are preassembled with the system for reconstitution).
ADVATE u sustavu BAXJECT III: Jedno pakiranje sastoji se od sustava BAXJECT III spremnog za uporabu, u hermetički zatvorenom blisteru (bočica s praškom i bočica s 5 ml otapala već su pričvršćene na sustav za rekonstituciju).
ADVATE is a white to off-white friable powder.
ADVATE je rastresit prašak bijele do gotovo bijele boje.
ADVATE is to be administered intravenously after reconstitution of the product.
Nakon rekonstitucije lijeka, ADVATE se treba primijeniti intravenski.
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 2 ml solvent and a device for reconstitution (BAXJECT II).
ADVATE s uređajem BAXJECT II: Jedno pakiranje sastoji se od bočice s praškom, bočice s 2 ml otapala i uređaja za rekonstituciju (BAXJECT II).
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 5 ml solvent and a device for reconstitution (BAXJECT II).
ADVATE s uređajem BAXJECT II: Jedno pakiranje sastoji se od bočice s praškom, bočice s 5 ml otapala i uređaja za rekonstituciju (BAXJECT II).
Adve rse re action
Nuspojava
Adverse affects observed in animal studies occurred at exposure levels appreciably lower than the clinical exposure levels to eslicarbazepine (the principal and pharmacologically active metabolite of eslicarbazepine acetate).
Primjećene nuspojave u studijama na životinjama pojavljuju se na razini izloženosti znatno nižoj od razine kliničke izloženosti eslikarbazepinu (glavni i farmakološki aktivni metabolit eslikarbazepinacetata).
Adverse central nervous system reactions observed in patients treated with asparaginase-containing therapy protocols include changes in EEG, seizures, dizziness, somnolence, coma and headache.
Nuspojave središnjeg živčanog sustava opažene u bolesnika liječenih terapijskim protokolima koji sadrže asparaginazu, uključuju promjene EEG-a, napadaje, omaglicu, somnolenciju, komu i glavobolju.
Adverse Drug Reaction
Nuspojava
Adverse Drug Reaction
Nuspojava lijeka
Adverse Drug Reaction
Nuspojava na lijek
Adverse drug reaction
Nuspojave
Adverse Drug Reaction
Nuspojave na lijek
Adverse Drug Reaction (ADR)
Nuspojava na lijek
Adverse drug reaction reported post-marketing only (i.e. not in clinical trials) are presented with a frequency of not known.
Za nuspojave prijavljene samo nakon stavljanja lijeka na tržište (tj. ne u kliničkim ispitivanjima) učestalost je nepoznata.
Adverse drug reaction reporting forms Health care Professional information
Formular za dojavu o nuspojavama Informacije za zdravstvene radnike
Adverse drug reactions
Nuspojava
Adverse drug reactions
Nuspojave
Adverse drug reactions
Nuspojave na lijek
Adverse Drug Reactions
Nuspojave na lijekove
Adverse drug reactions (ADR) reported with Pixuvri are from final data from all completed studies.
Nuspojave zabilježene primjenom Pixuvria potječu iz konačnih rezultata svih dovršenih ispitivanja.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Leganto are nausea, application site reactions, asthenic conditions and headache.
Nuspojave zabilježene u više od 10% bolesnika liječenih Legantom jesu mučnina, povraćanje, reakcija na mjestu primjene, somnolencija, omaglica i glavobolja.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Leganto transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
Nuspojave zabilježene u više od 10% bolesnika liječenih Legantom jesu mučnina, povraćanje, reakcije na mjestu primjene, somnolencija, omaglica i glavobolja.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, asthenic conditions and headache.
Nuspojave zabilježene u više od 10% bolesnika liječenih Neuprom jesu mučnina, povraćanje, reakcija na mjestu primjene, somnolencija, omaglica i glavobolja.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
Nuspojave zabilježene u više od 10% bolesnika liječenih Neuprom jesu mučnina, povraćanje, reakcije na mjestu primjene, somnolencija, omaglica i glavobolja.
Adverse Drug Reactions (ADRs) which were reported in patients with advanced gastric cancer, mCRC or NSCLC are listed below by MedDRA body system organ class, frequency and grade of severity.
Nuspojave na lijek prijavljene u bolesnika s uznapredovalim rakom želuca, metastatskim kolorektalnim rakom ili rakom pluća nemalih stanica navedene su u nastavku prema MedDRA klasifikaciji organskih sustava, učestalosti i stupnju težine.
Adverse drug reactions are listed according to system organ class (SOC) in MedDRA.
Nuspojave su navedene prema MedDRA-inoj klasifikaciji organskih sustava.
Adverse drug reactions during clinical trials
Nuspojave u kliničkim ispitivanjima
Adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.
Nuspojave nakon primjene Econora uglavnom su povezane s pasminama i mješancima danskog i/ili švedskog landrasa.
Adverse drug reactions for both treatments, dabigatran etexilate and warfarin, are counted from the first intake of dabigatran etexilate or warfarin after the parenteral therapy has been discontinued (oral only treatment period).
Nuspojave oba liječenja, dabigatraneteksilatom i varfarinom, računaju se od prvog unosa dabigatraneteksilata odnosno varfarina, nakon prekida parenteralnog liječenja (razdoblje isključivo peroralnog liječenja).
Adverse drug reactions for SIRTURO were identified from pooled Phase IIb clinical trial data (both controlled and uncontrolled) containing 335 patients who received SIRTURO in combination with a background regimen of tuberculosis medicinal products.
Nuspojave na lijek SIRTURO identificirane su iz udruženih podataka kliničkih ispitivanja Faze IIb (iz oba i kontrolirana i nekontrolirana) koja su uključivala 335 bolesnika koji su primili SIRTURO u kombinaciji s lijekovima za osnovno liječenje tuberkuloze.
Adverse drug reactions from clinical studies (Table 1) are listed by MedDRA system organ class.
Nuspojave na lijek iz kliničkih ispitivanja (Tablica 1) navedene su prema organskom sustavu po MedDRA-i.
Adverse drug reactions have occurred following the use of Econor.
Nakon primjene Econora pojavile su se nuspojave u svinja.
Adverse drug reactions have occurred in pigs following the use of Econor.
Nakon primjene Econora pojavile su se nuspojave u svinja.
Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the BR- CAP arm and with at least a possible or probable causal relationship to the components of the BR-CAP arm, are listed in Table 8 below.
Nuspojave identificirane poput onih s incidencijom ≥ 1%, slične ili veće incidencije u BR-CAP skupini s barem mogućom ili vjerojatnom uzročnom povezanošću s komponentama skupine BR-CAP, navedene su u Tablici 8 ispod.
Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the BzmbR-CAP arm and with at least a possible or probable causal relationship to the components of the BzmbR-CAP arm, are listed in Table 8 below.
Nuspojave identificirane poput onih s incidencijom ≥ 1 %, slične ili veće incidencije u BzmbR-CAP skupini s barem mogućom ili vjerojatnom uzročnom povezanošću s komponentama skupine BzmbR- CAP navedene su u Tablici 8 ispod.
Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the BzR-CAP arm and with at least a possible or probable causal relationship to the components of the BzR-CAP arm, are listed in Table 8 below.
Nuspojave identificirane poput onih s incidencijom ≥ 1%, slične ili veće incidencije u BzR-CAP skupini s barem mogućom ili vjerojatnom uzročnom povezanošću s komponentama skupine BzR- CAP, navedene su u Tablici 8 ispod.
Adverse drug reactions identified during the post-marketing experience with Caelyx
Nuspojave identificirane tijekom postmarketinškog iskustva s Caelyxom
Adverse drug reactions identified with Viekirax in combination with dasabuvir with and without ribavirin
Nuspojave na lijek utvrđene kod primjene lijeka Viekirax u kombinaciji s dasabuvirom, s ribavirinom ili bez njega
Adverse Drug Reactions in Female Partners
Nuspojave u ženskih partnerica
Adverse Drug Reactions in Male Glans-penis-treated Subjects
Nuspojave na lijek u muškaraca liječenih primjenom na glavić penisa
Adverse drug reactions including lack of efficacy
Nuspojave lijeka uključujući izostanak djelotvornosti
Adverse drug reactions reported for tobramycin nebuliser solution are listed in Table 1.
Nuspojave zabilježene pri primjeni atomizirane otopine tobramicina navedene su u Tablici 1.
Adverse drug reactions reported in 293 AML patients treated with Dacogen are summarised in Table 1.
Nuspojave na lijek prijavljene u 293 bolesnika s AML liječenih Dacogenom, sažeto su navedene u tablici 1.
Adverse drug reactions reported in AURAa studies
Nuspojave prijavljene u AURAa ispitivanjima
Adverse drug reactions reported in patients with history of end stage renal disease were similar to those reported in the general patient population.
Prijavljene nuspojave lijeka kod bolesnika sa završnim stadijem bubrežne bolesti jednake su prijavljenim nuspojavama u općoj populaciji bolesnika.
Adverse drug reactions reported related to Pixuvri in completed Pixuvri studies by frequency
Nuspojave povezane s primjenom Pixuvria zabilježene u dovršenim ispitivanjima Pixuvria prema učestalosti
Adverse Drug Reactions Reported with Intuniv
Nuspojave prijavljene uz Intuniv
Adverse drug reactions such as nausea, vomiting, diarrhoea and sweating were reported.
Opisane su i nuspojave poput mučnine, povraćanja, proljeva i znojenja.
Adverse drug reactions such as somnolence and vertigo have been reported in INTELENCE treated subjects at incidences similar to placebo (see section 4.8).
Međutim, prijavljena je nuspojava poput somnolencije i vrtoglavice kod nekih bolesnika tijekom liječenja INTELENCE-om u incidenciji jednakoj kao uz placebo (vidjeti dio 4.8).
Adverse drug reactions*
Nuspojave na lijek
Adverse Drug Reactions, from clinical trials and spontaneous reports
Nuspojave iz kliničkih ispitivanja i spontanih izvješća
Adverse effects not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to human use was myelofibrosis of the bone marrow in the mouse carcinogenicity study.
Nuspojava koja nije bila opažena u kliničkim ispitivanjima, ali je bila primijećena kod životinja, pri razinama izloženosti koje su bile slične kliničkoj razini izloženosti i možda važna za primjenu u ljudi, bila je mijelofibroza koštane srži u ispitivanju kancerogenosti u miša.
Adverse effects not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to human use, was myelofibrosis of the bone marrow in the mouse carcinogenicity study.
Nuspojava koja nije bila opažena u kliničkim ispitivanjima, ali je bila primijećena kod životinja pri razinama izloženosti koje su bile slične kliničkoj razini izloženosti i možda važna za primjenu u ljudi, bila je mijelofibroza koštane srži u ispitivanju kancerogenosti u miša.
Adverse effects not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to human use, was myelofibrosis of the bone marrow in the mouse carcinogenicity study.
Nuspojava koja nije bila opažena u kliničkim ispitivanjima, ali je bila primijećena kod životinja, pri razinama izloženosti koje su bile slične kliničkoj razini izloženosti i možda važna za primjenu u ljudi, bila je mijelofibroza koštane srži u ispitivanju kancerogenosti u miša.
Adverse event
Nuspojava
Adverse event reactions for bivalirudin are listed by system organ class in Table 1.
Nuspojave na bivalirudin navedene su prema klasifikaciji organskih sustava u tablici 1.
Adverse event reporting
Prijavljivanje štetnih događaja
Adverse event reporting forms
Obrasci za prijavljivanje štetnog događaja.
Adverse Events
Nuspojava
adverse events (including visual
pratiti znakovi estrogenske deficijencije.
Adverse events applicable to all indications:
Nuspojave primjenjive na sve indikacije:
adverse events associated with
rifabutina može biti potrebno
Adverse events associated with the use of Panretin gel in AIDS-related KS occurred almost exclusively at the site of application.
Nuspojave povezane s primjenom Panretina kod KS povezanog s AIDS-om nastale su gotovo isključivo na mjestu primjene.
Adverse events include verbatim terms in parentheses.
Nuspojave uključuju verbatim izraze u zagradama.
adverse events including
liječenja i nuspojava.
Adverse events observed included granulocytopenia, dizziness and paraesthesia.
Primijećeni su štetni događaji koji uključuju granulocitopeniju, vrtoglavicu i paresteziju.
Adverse events of nausea,
opasnih reakcija povezanih s
Adverse events of nausea, dizziness, hypotension and syncope have been observed following co- administration of trazodone and ritonavir in this study.
Nuspojave u smislu mučnine, omaglice, hipotenzije i sinkope primijećene su nakon istodobne primjene trazodona i ritonavira u ovom ispitivanju.
Adverse Events of Special Interest (PTs)
Neželjeni događaji od posebnog interesa (PT)
Adverse Events of Special Interest stratified according to type of report (medically confirmed or non-medically confirmed).
Štetni događaji od posebnog značaja razvrstani prema vrsti izvješća (medicinski potvrđeno ili medicinski nepotvrđeno).